United States: Supreme Court Grants Cert In BPCIA Case

On January 13, 2017, the Supreme Court granted certiorari to two related petitions brought by Amgen, Inc. and Sandoz, Inc. to resolve disputes regarding the interpretation of the Biologics Price Competition and Innovation Act (BPCIA). In 2009, Congress passed the BPCIA to create an abbreviated regulatory pathway through which the Food and Drug Administration (FDA) can approve a biological pharmaceutical product as a "biosimilar." 42 U.S.C. § 262(a), (k). A biosimilar is a drug product that is highly similar to an approved biological product or "reference product." 42 U.S.C. § 262(i)(2).

In addition to creating a regulatory pathway for biosimilar approvals, the BPCIA also established procedures for resolving patent disputes between a biosimilar applicant ("Applicant") and a reference product sponsor ("Sponsor"). 42 U.S.C. § 262(l). Under the patent dispute resolution scheme, an Applicant provides the Sponsor with confidential access to its abbreviated biologics license application (aBLA) and manufacturing information no later than 20 days after the FDA accepts the aBLA for review. Id. at § 262(1)(2). This information assists the Sponsor in evaluating potential claims for infringement. After the initial disclosure, the statute then establishes the parameters for a series of exchanges between the parties to identify and narrow the relevant patents and the parties' respective positions, after which the Sponsor has 30 days to sue the Applicant. Id. at § 262 (l)(3)-(6). The statute also provides that an Applicant "shall" provide notice to the Sponsor of its intent to market the biosimilar 180 days before the date of the first commercial marketing of the biological product licensed under subsection (k). Id. at § 262(l)(8)(A).    

In this case, Sandoz sought FDA approval of a biosimilar for Amgen's biological product Neupogen. On July 7, 2014, the FDA informed Sandoz that it accepted Sandoz's aBLA for review. The next day, Sandoz notified Amgen that it had filed an aBLA referencing Neupogen, that it believed it would be approved in early to mid-2015 and that it intended to launch its biosimilar product immediately after receiving FDA approval. However, Sandoz refused to provide Amgen with a copy of its aBLA or manufacturing information consistent with the provisions of Section 262(l)(2). On March 6, 2015, the FDA approved Sandoz's aBLA for all previously approved uses of Amgen's Neupogen, at which time, Sandoz again provided Amgen with notice of an intent to market its biosimilar.

In October 2014, Amgen sued Sandoz for patent infringement and accused Sandoz of violating the BPCIA for failing to provide the information required under Section 262(l)(2) and for providing a premature, ineffective notice of commercial marketing. Sandoz then filed a counterclaim seeking a declaratory judgment that it correctly interpreted the BPCIA as permitting its preapproval notice of commercial marketing and refusal to provide information to Amgen. Amgen later sought a preliminary injunction.

Following cross-motions for judgment on the pleadings, the district court granted partial judgment in favor of Sandoz. In particular, the district court held that (1) the BPCIA allowed an Applicant to withhold its aBLA and manufacturing information; (2) an Applicant's decision to withhold that information triggered the relief provided in Section 262(l)(9)(C) (i.e., the right of the Sponsor to file a declaratory suit for infringement); (3) no injunctive relief was available; and (4) an Applicant may give notice of commercial marketing under Section 262 (l)(8)(A) prior to obtaining FDA approval.

On appeal, a divided panel of the Federal Circuit held that Sandoz did not violate the BPCIA when it refused to provide Amgen with its aBLA and manufacturing information, and that the statutory consequence for such failure was Amgen's right to bring an infringement action under Section 262(l)(9)(C). Regarding the requirement for notice of commercial marketing, the Federal Circuit held that an Applicant may give notice of commercial marketing only after the FDA licenses its product. In other words, Sandoz's preapproval notice of commercial marketing was ineffective. The ultimate effect of this aspect of the Federal Circuit's decision is that an Applicant must wait at least 180 days from the date it receives approval for its biosimilar product before it can commercially market that product.

Both Amgen and Sandoz filed petitions seeking Supreme Court review of different aspects of the Federal Circuit's decision. Sandoz challenged the Federal Circuit's interpretation of the notice of commercial marketing requirement, while Amgen filed a conditional cross-petition seeking review of the Federal Circuit's interpretation of the disclosure requirements.

In agreeing to hear the case, the Supreme Court certified questions presented by both parties and allotted the case a full hour of argument time.

The question presented by Sandoz's Petition is:        

Whether notice of commercial marketing given before FDA approval can be effective and whether, in any event, treating Section 262(l)(8)(A) as a standalone requirement and creating an injunctive remedy that delays all biosimilars by 180 days after approval is improper.

The question presented by Amgen's Conditional Cross-Petition is:

Is an Applicant required by 42 U.S.C. § 262(l)(2)(A) to provide the Sponsor with a copy of its biologics license application and related manufacturing information, which the statute says the Applicant "shall provide," and, where an Applicant fails to provide that required information, is the Sponsor's sole recourse to commence a declaratory-judgment action under 42 U.S.C. § 262(l)(9)(C) and/or a patent-infringement action under 35 U.S.C. § 271 (e)(2)(C)(ii)?

Sandoz Inc. v. Amgen Inc., C.A. No. 15-1039, Amgen Inc. v. Sandoz Inc., C.A. No. 15-1195

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions